$1.36 Billion is the total value of Consonance Capital Management LP's 24 reported holdings in Q4 2018. The portfolio turnover from Q3 2018 to Q4 2018 was 63.6% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
KPTI | Sell | KARYOPHARM THERAPEUTICS INC | $45,070,000 | -45.2% | 4,810,078 | -0.4% | 3.32% | -25.1% |
SPPI | Sell | SPECTRUM PHARMACEUTICALS INC | $25,979,000 | -73.5% | 2,969,027 | -49.1% | 1.91% | -63.8% |
PACB | Sell | PACIFIC BIOSCIENCES CALIF IN | $18,168,000 | -75.1% | 2,455,114 | -81.8% | 1.34% | -66.1% |
STML | Sell | STEMLINE THERAPEUTICS INC | $10,980,000 | -75.9% | 1,155,793 | -57.9% | 0.81% | -67.1% |
INVA | Exit | INNOVIVA INC | $0 | – | -1,002,675 | -100.0% | -0.82% | – |
TBPH | Exit | THERAVANCE BIOPHARMA INC | $0 | – | -731,909 | -100.0% | -1.29% | – |
RARX | Exit | RA PHARMACEUTICALS INC | $0 | – | -1,454,761 | -100.0% | -1.42% | – |
VSTM | Exit | VERASTEM INC | $0 | – | -5,154,224 | -100.0% | -2.01% | – |
NUVA | Exit | NUVASIVE INC | $0 | – | -1,089,523 | -100.0% | -4.16% | – |
NVRO | Exit | NEVRO CORP | $0 | – | -1,446,333 | -100.0% | -4.44% | – |
PBYI | Exit | PUMA BIOTECHNOLOGY INC | $0 | – | -2,303,455 | -100.0% | -5.69% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-02-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
UNITED THERAPEUTICS CORP DEL | 29 | Q2 2022 | 15.9% |
ADMA BIOLOGICS INC | 27 | Q4 2020 | 2.3% |
RETROPHIN INC | 23 | Q1 2020 | 11.3% |
ANI PHARMACEUTICALS INC | 23 | Q3 2019 | 7.9% |
VERICEL CORP | 21 | Q4 2019 | 5.5% |
AMARIN CORP PLC | 14 | Q3 2019 | 14.4% |
GLOBUS MED INC | 13 | Q2 2022 | 24.7% |
ORTHOFIX INTL N V | 13 | Q3 2016 | 9.7% |
PACIFIC BIOSCIENCES CALIF IN | 13 | Q4 2018 | 9.7% |
CATALYST PHARM PARTNERS INC | 13 | Q3 2019 | 9.4% |
View Consonance Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Surrozen, Inc./DESold out | December 15, 2022 | 0 | 0.0% |
ADMA BIOLOGICS, INC. | February 14, 2022 | 1,289,481 | 1.4% |
ASSEMBLY BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
CASI Pharmaceuticals, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
Cellectar Biosciences, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
Gamida Cell Ltd.Sold out | February 14, 2022 | 0 | 0.0% |
GenMark Diagnostics, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
Protagonist Therapeutics, IncSold out | February 14, 2022 | 0 | 0.0% |
Sio Gene Therapies Inc.Sold out | February 14, 2022 | 0 | 0.0% |
Consonance-HFW Acquisition Corp. | April 27, 2021 | 1,000,000 | 10.4% |
View Consonance Capital Management LP's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
4 | 2022-12-15 |
SC 13D/A | 2022-12-15 |
13F-HR | 2022-11-14 |
13F-HR | 2022-08-15 |
13F-HR | 2022-05-16 |
13F-HR | 2022-02-14 |
SC 13G/A | 2022-02-14 |
SC 13G/A | 2022-02-14 |
SC 13G/A | 2022-02-14 |
SC 13G/A | 2022-02-14 |
View Consonance Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.